Synaptogenix Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	28.66	37.48	34.21	5.8	17.38	28.85
Short-Term Investments	1.44	0	0	0	0	0
Cash & Cash Equivalents	30.1	37.48	34.21	5.8	17.38	28.85
Cash Growth	-19.69%	9.54%	490.40%	-66.66%	-39.76%	-
Other Current Assets	0.43	1.11	1.29	0.93	0.49	0.6
Total Current Assets	30.53	38.59	35.5	6.73	17.88	29.46
Property, Plant & Equipment	0.02	0.02	0.02	0.02	0.02	0.02
Long-Term Investments	0.56	0	0	0	0	0
Total Long-Term Assets	0.58	0.02	0.02	0.02	0.02	0.02
Total Assets	31.11	38.61	35.52	6.75	17.9	29.48
Accounts Payable	0.44	0.66	1.3	1.26	0.41	2.9
Other Current Liabilities	3.83	0.65	0.7	0.35	0.07	0.06
Total Current Liabilities	4.28	1.31	1.99	1.61	0.48	2.96
Other Long-Term Liabilities	1.25	1.88	0	0	0	0
Total Long-Term Liabilities	1.25	1.88	0	0	0	0
Total Liabilities	5.53	3.19	1.99	1.61	0.48	2.96
Retained Earnings	-33.61	-19.83	-14.14	-1.53	0	-73.68
Comprehensive Income	0	0	0	0	0	0
Shareholders' Equity	24.35	32.69	33.53	5.14	17.42	26.52
Net Cash / Debt	30.1	37.48	34.21	5.8	17.38	28.85
Net Cash / Debt Growth	-19.69%	9.54%	490.40%	-66.66%	-39.76%	-
Net Cash Per Share	64.58	134.06	170.55	115.20	345.55	358.41
Working Capital	26.26	37.27	33.51	5.12	17.4	26.5
Book Value Per Share	52.24	116.94	167.14	102.15	346.28	329.43

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).